The intuitive case for β-blockers in patients with ESRD

Seminars in Dialysis

Volumn 25, Issue 1, 2012, Pages 15-21

  McQuillan, Rory F ^a   Chan, Christopher T ^a  

^a TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

CANADA; CAUSE OF DEATH; CHRONIC KIDNEY FAILURE; HUMAN; MORTALITY; RENAL REPLACEMENT THERAPY; REVIEW; RISK FACTOR; SUDDEN DEATH;

ADRENERGIC BETA-ANTAGONISTS; CAUSE OF DEATH; DEATH, SUDDEN, CARDIAC; HUMANS; KIDNEY FAILURE, CHRONIC; ONTARIO; RENAL DIALYSIS; RISK FACTORS;

EID: 84856274350     PISSN: 08940959     EISSN: 1525139X     Source Type: Journal    
DOI: 10.1111/j.1525-139X.2011.01016.x     Document Type: Review

References (79)

1. U.S. Renal Data System: USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2010.
2. Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G, Ritz E: Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353(3):238-248, 2005.
3. Cheung AK, Sarnak MJ, Yan G, Berkoben M, Heyka R, Kaufman A, Lewis J, Rocco M, Toto R, Windus D, Ornt D, Levey AS: Cardiac diseases in maintenance hemodialysis patients: results of the HEMO study. Kidney Int 65(6):2380-2389, 2004.
4. Myerburg R: Cardiac Arrest and Sudden Cardiac Death Braunwald's Heart Disease. A Textbook of Cardiovascular Medicine. Philadelphia, PA: Elsevier Saunders, 2005.
5. Chugh SS, Jui J, Gunson K, Stecker EC, John BT, Thompson B, Ilias N, Vickers C, Dogra V, Daya M, Kron J, Zheng ZJ, Mensah G, McAnulty J: Current burden of sudden cardiac death: multiple source surveillance versus retrospective death certificate-based review in a large U.S. community. J Am Coll Cardiol 44(6):1268-1275, 2004.
6. Priori SG, Aliot E, Blomstrom-Lundqvist C, Bossaert L, Breithardt G, Brugada P, Camm AJ, Cappato R, Cobbe SM, Di Mario C, Maron BJ, McKenna WJ, Pedersen AK, Ravens U, Schwartz PJ, Trusz-Gluza M, Vardas P, Wellens HJ, Zipes DP: Task force on sudden cardiac death of the European Society of Cardiology. Eur Heart J 22(16):1374-1450, 2001.
7. Thomas AC, Knapman PA, Rowley JM, Turner DR: Community study of the causes of "natural" sudden death. BMJ 297(6661):1453-1456, 1988.
8. Leach IH, Blundell JW, Krikler DM, Davies MJ: Acute ischaemic lesions in death due to ischaemic heart disease. An autopsy study of 333 cases of out-of-hospital death. Eur Heart J 16(9):1181-1185, 1995.
9. Dubner SJ, Pinski S, Palma S, Elencwajg B, Tronge JE: Ambulatory electrocardiographic findings in out-of-hospital cardiac arrest secondary to coronary artery disease. Am J Cardiol 64(12):801-806, 1989.
10. Foley RN, Parfrey PS, Sarnak MJ: Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32(5 Suppl 3):S112-S119, 1998.
11. Silber S, Albertsson P, Aviles FF, Camici PG, Colombo A, Hamm C, Jorgensen E, Marco J, Nordrehaug JE, Ruzyllo W, Urban P, Stone GW, Wijns W: Guidelines for percutaneous coronary interventions. The Task Force for percutaneous coronary interventions of the European Society of Cardiology. Eur Heart J 26(8):804-847, 2005.
12. Herzog CA, Ma JZ, Collins AJ, Gilbertson DT: Comparative survival of dialysis patients in the United States after coronary angioplasty, coronary artery stenting, and coronary artery bypass surgery and impact of diabetes. Circulation 106(17):2207-2211, 2002.
13. Herzog CA, Strief JW, Collins AJ: Cause-specific mortality of dialysis patients after coronary revascularization: why don't dialysis patients have better survival after coronary intervention? Nephrol Dial Transplant 23(8):2629-2633, 2008.
14. Pun PH, Lehrich RW, Smith SR, Middleton JP: Predictors of survival after cardiac arrest in outpatient hemodialysis clinics. Clin J Am Soc Nephrol 2(3):491-500, 2007.
15. Friedman LM, Byington RP, Capone RJ, Furberg CD, Goldstein S, Lichstein E: Effect of propranolol in patients with myocardial infarction and ventricular arrhythmia. J Am Coll Cardiol 7(1):1-8, 1986.
16. Nuttall SL, Toescu V, Kendall MJ: Beta blockade after myocardial infarction. Beta blockers have key role in reducing morbidity and mortality after infarction. BMJ 320(7234):581, 2000.
17. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH: The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 334(21):1349-1355, 1996.
18. Pun PH, Smarz TR, Honeycutt EF, Shaw LK, Al-Khatib SM, Middleton JP: Chronic kidney disease is associated with increased risk of sudden cardiac death among patients with coronary artery disease. Kidney Int 76(6):652-658, 2009.
19. Grassi G, Quarti-Trevano F, Seravalle G, Arenare F, Volpe M, Furiani S, Dell'Oro R, Mancia G: Early sympathetic activation in the initial clinical stages of chronic renal failure. Hypertension 57(4):846-851, 2011.
20. Bennett DL, Koltzenburg M, Priestley JV, Shelton DL, McMahon SB: Endogenous nerve growth factor regulates the sensitivity of nociceptors in the adult rat. Eur J Neurosci 10(4):1282-1291, 1998.
21. Cerasola G, Vecchi M, Mule G, Cottone S, Mangano MT, Andronico G, Contorno A, Parrino I, Renda F, Pavone G: Sympathetic activity and blood pressure pattern in autosomal dominant polycystic kidney disease hypertensives. Am J Nephrol 18(5):391-398, 1998.
22. Hausberg M, Kosch M, Harmelink P, Barenbrock M, Hohage H, Kisters K, Dietl KH, Rahn KH: Sympathetic nerve activity in end-stage renal disease. Circulation 106(15):1974-1979, 2002.
23. Faber JE, Brody MJ: Neural contribution to renal hypertension following acute renal artery stenosis in conscious rats. Hypertension 5(2 Pt 2):I155-I164, 1983.
24. Miyajima E, Yamada Y, Yoshida Y, Matsukawa T, Shionoiri H, Tochikubo O, Ishii M: Muscle sympathetic nerve activity in renovascular hypertension and primary aldosteronism. Hypertension 17(6 Pt 2):1057-1062, 1991.
25. Converse RL Jr, Jacobsen TN, Toto RD, Jost CM, Cosentino F, Fouad-Tarazi F, Victor RG: Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 327(27):1912-1918, 1992.
26. Ye S, Ozgur B, Campese VM: Renal afferent impulses, the posterior hypothalamus, and hypertension in rats with chronic renal failure. Kidney Int 51(3):722-727, 1997.
27. Campese VM, Kogosov E: Renal afferent denervation prevents hypertension in rats with chronic renal failure. Hypertension 25(4 Pt 2):878-882, 1995.
28. Campese VM, Kogosov E, Koss M: Renal afferent denervation prevents the progression of renal disease in the renal ablation model of chronic renal failure in the rat. Am J Kidney Dis 26(5):861-865, 1995.
29. Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Bohm M: Renal sympathetic denervation in patients with treatment-resistant hypertension (the Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 376(9756):1903-1909, 2010.
30. Xu J, Li G, Wang P, Velazquez H, Yao X, Li Y, Wu Y, Peixoto A, Crowley S, Desir GV: Renalase is a novel, soluble monoamine oxidase that regulates cardiac function and blood pressure. J Clin Invest 115(5):1275-1280, 2005.
31. Benedict CR, Shelton B, Johnstone DE, Francis G, Greenberg B, Konstam M, Probstfield JL, Yusuf S: Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction. SOLVD Investigators. Circulation 94(4):690-697, 1996.
32. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, Simon AB, Rector T: Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 311(13):819-823, 1984.
33. Francis GS, Cohn JN, Johnson G, Rector TS, Goldman S, Simon A: Plasma norepinephrine, plasma renin activity, and congestive heart failure. Relations to survival and the effects of therapy in V-HeFT II. The V-HeFT VA Cooperative Studies Group. Circulation 87(6 Suppl):VI40-VI48, 1993.
34. Kaye DM, Lefkovits J, Jennings GL, Bergin P, Broughton A, Esler MD: Adverse consequences of high sympathetic nervous activity in the failing human heart. J Am Coll Cardiol 26(5):1257-1263, 1995.
35. Rouleau JL, Packer M, Moye L, de Champlain J, Bichet D, Klein M, Rouleau JR, Sussex B, Arnold JM, Sestier F, et al.: Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril. J Am Coll Cardiol 24(3):583-591, 1994.
36. Zoccali C, Mallamaci F, Parlongo S, Cutrupi S, Benedetto FA, Tripepi G, Bonanno G, Rapisarda F, Fatuzzo P, Seminara G, Cataliotti A, Stancanelli B, Malatino LS: Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation 105(11):1354-1359, 2002.
37. Han J, Garciadejalon P, Moe GK: Adrenergic effects on ventricular vulnerability. Circ Res 14:516-524, 1964.
38. Podzuweit T: Catecholamine-cyclic-AMP-Ca+-induced ventricular tachycardia in the intact pig heart. Basic Res Cardiol 75(6):772-779, 1980.
39. Podzuweit T, Louw GC, Shanley BC: Catecholamine/cyclic AMP/Ca2+ induces arrhythmias in the healthy pig heart. Adv Myocardiol 2:133-143, 1980.
40. Mann DL, Kent RL, Parsons B, Cooper GT: Adrenergic effects on the biology of the adult mammalian cardiocyte. Circulation 85(2):790-804, 1992.
41. Terrenoire C, Clancy CE, Cormier JW, Sampson KJ, Kass RS: Autonomic control of cardiac action potentials: role of potassium channel kinetics in response to sympathetic stimulation. Circ Res 96(5):e25-e34, 2005.
42. Yoshioka K, Gao DW, Chin M, Stillson C, Penades E, Lesh M, O'Connell W, Dae M: Heterogeneous sympathetic innervation influences local myocardial repolarization in normally perfused rabbit hearts. Circulation 101(9):1060-1066, 2000.
43. Vracko R, Thorning D, Lu LS, Su MJ, Lin CW, Lin SF, Chen LS, Fishbein MC, Chen PS, Lee YT: Nerve fibers in human myocardial scars. Hum Pathol 22(2):138-146, 1991.
44. Liu YB, Wu CC, Frederickson RG: Sympathetic nerve sprouting, electrical remodeling, and increased vulnerability to ventricular fibrillation in hypercholesterolemic rabbits. Circ Res 92(10):1145-1152, 2003.
45. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE: The prognostic importance of left ventricular geometry in uremic cardiomyopathy. J Am Soc Nephrol 5(12):2024-2031, 1995.
46. Foley RN, Curtis BM, Randell EW, Parfrey PS: Left ventricular hypertrophy in new hemodialysis patients without symptomatic cardiac disease. Clin J Am Soc Nephrol 5(5):805-813, 2010.
47. Sano M, Minamino T, Toko H, Miyauchi H, Orimo M, Qin Y, Akazawa H, Tateno K, Kayama Y, Harada M, Shimizu I, Asahara T, Hamada H, Tomita S, Molkentin JD, Zou Y, Komuro I: p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload. Nature 446(7134):444-448, 2007.
48. Diwan A, Wansapura J, Syed FM, Matkovich SJ, Lorenz JN, Dorn GW, 2nd: Nix-mediated apoptosis links myocardial fibrosis, cardiac remodeling, and hypertrophy decompensation. Circulation 117(3):396-404, 2008.
49. Glassock RJ, Pecoits-Filho R, Barberato SH: Left ventricular mass in chronic kidney disease and ESRD. Clin J Am Soc Nephrol 4(Suppl 1):S79-S91, 2009.
50. Zoccali C, Benedetto FA, Mallamaci F, Tripepi G, Giacone G, Cataliotti A, Seminara G, Stancanelli B, Malatino LS: Prognostic impact of the indexation of left ventricular mass in patients undergoing dialysis. J Am Soc Nephrol 12(12):2768-2774, 2001.
51. Zoccali C, Benedetto FA, Mallamaci F, Tripepi G, Giacone G, Stancanelli B, Cataliotti A, Malatino LS: Left ventricular mass monitoring in the follow-up of dialysis patients: prognostic value of left ventricular hypertrophy progression. Kidney Int 65(4):1492-1498, 2004.
52. London GRM, Pannier B, Guerin AP, Blacher J, Marchais SJ, Darne B, Metivier F, Adda H, Safar ME: Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: follow-up of an interventional study. J Am Soc Nephrol 12(12):2759-2767, 2001.
53. Kimmel PL, Miller G, Mendelson WB: Sleep apnea syndrome in chronic renal disease. Am J Med 86(3):308-314, 1989.
54. Bradley TD, Floras JS: Pathophysiologic and therapeutic implications of sleep apnea in congestive heart failure. J Card Fail 2(3):223-240, 1996.
55. Masuda T, Murata M, Honma S, Iwazu Y, Sasaki N, Ogura M, Onishi A, Ando Y, Muto S, Shimada K, Kario K, Kusano E, Asano Y: Sleep-disordered breathing predicts cardiovascular events and mortality in hemodialysis patients. Nephrol Dial Transplant 26(7):2289-2295, 2011.
56. Machackova J, Sanganalmath SK, Sanganalmath SK, Barta J, Dhalla KS, Dhalla NS: Amelioration of cardiac remodeling in congestive heart failure by beta-adrenoceptor blockade is associated with depression in sympathetic activity. Cardiovasc Toxicol 10(1):9-16, 2010.
57. Thandroyen FT, Worthington MG, Higginson LM, Opie LH: The effect of alpha- and beta-adrenoceptor antagonist agents on reperfusion ventricular fibrillation and metabolic status in the isolated perfused rat heart. J Am Coll Cardiol 1(4):1056-1066, 1983.
58. Foley RN, Herzog CA, Collins AJ: Blood pressure and long-term mortality in United States hemodialysis patients: USRDS Waves 3 and 4 Study. Kidney Int 62(5):1784-1790, 2002.
59. Abbott KC, Trespalacios FC, Agodoa LY, Taylor AJ, Bakris GL: Beta-blocker use in long-term dialysis patients: association with hospitalized heart failure and mortality. Arch Intern Med 164(22):2465-2471, 2004.
60. Berger AK, Duval S, Krumholz HM: Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction. J Am Coll Cardiol 42(2):201-208, 2003.
61. Koch M, Thomas B, Tschope W, Ritz E: Survival and predictors of death in dialysed diabetic patients. Diabetologia 36(10):1113-1117, 1993.
62. Wali RK, Iyengar M, Beck GJ, Chartyan DM, Chonchol M, Lukas MA, Cooper C, Himmelfarb J, Weir MR, Berl T, Henrich WL, Cheung AK: Efficacy and safety of carvedilol in treatment of heart failure with chronic kidney disease: a meta-analysis of randomized trials. Circ Heart Fail 4(1):18-26, 2011.
63. Cice G, Ferrara L, D'Andrea A, D'Isa S, Di Benedetto A, Cittadini A, Russo PE, Golino P, Calabro R: Carvedilol increases two-year survivalin dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial. J Am Coll Cardiol 41(9):1438-1444, 2003.
64. Charytan D, Mauri L, Agarwal A, Servoss S, Scirica B, Kuntz RE: The use of invasive cardiac procedures after acute myocardial infarction in long-term dialysis patients. Am Heart J 152(3):558-564, 2006.
65. Hemmelgarn BR, Southern D, Culleton BF, Mitchell LB, Knudtson ML, Ghali WA: Survival after coronary revascularization among patients with kidney disease. Circulation 110(14):1890-1895, 2004.
66. Herzog CA, Li S, Weinhandl ED, Strief JW, Collins AJ, Gilbertson DT: Survival of dialysis patients after cardiac arrest and the impact of implantable cardioverter defibrillators. Kidney Int 68(2):818-825, 2005.
67. Miki S, Masumura H, Kaifu Y, Yuasa S: Pharmacokinetics and efficacy of carvedilol in chronic hemodialysis patients with hypertension. J Cardiovasc Pharmacol 18(Suppl 4):S62-S68, 1991.
68. Agarwal R: Supervised atenolol therapy in the management of hemodialysis hypertension. Kidney Int 55(4):1528-1535, 1999.
69. Flouvat B, Decourt S, Aubert P, Potaux L, Domart M, Goupil A, Baglin A: Pharmacokinetics of atenolol in patients with terminal renal failure and influence of haemodialysis. Br J Clin Pharmacol 9(4):379-385, 1980.
70. Gifford JD, Rutsky EA, Kirk KA, McDaniel HG: Control of serum potassium during fasting in patients with end-stage renal disease. Kidney Int 35(1):90-94, 1989.
71. Nowicki M, Miszczak-Kuban J: Nonselective beta-adrenergic blockade augments fasting hyperkalemia in hemodialysis patients. Nephron 91(2):222-227, 2002.
72. Sherman RA, Hwang ER, Bernholc AS, Eisinger RP: Variability in potassium removal by hemodialysis. Am J Nephrol 6(4):284-288, 1986.
73. Castellino P, Bia MJ, DeFronzo RA: Adrenergic modulation of potassium metabolism in uremia. Kidney Int 37(2):793-798, 1990.
74. Hamad A, Salameh M, Zihlif M, Feinfeld DA, Carvounis CP: Life-threatening hyperkalemia after intravenous labetolol injection for hypertensive emergency in a hemodialysis patient. Am J Nephrol 21(3):241-244, 2001.
75. Nowicki M, Szewczyk-Seifert G, Klimek D, Kokot F: Carvedilol does not modulate moderate exercise-induced hyperkalemia in hemodialysis patients. Clin Nephrol 57(5):352-358, 2002.
76. Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL: Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med 342(13):905-912, 2000.
77. Bangalore S, Parkar S, Grossman E, Messerli FH: A meta-analysis of 94, 492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus. Am J Cardiol 100(8):1254-1262, 2007.
78. Bakris GL, Fonseca V, Katholi RE, McGill JB, Messerli FH, Phillips RA, Raskin P, Wright JT, Jr, Oakes R, Lukas MA, Anderson KM, Bell DS: Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 292(18):2227-2236, 2004.
79. Floras JS: Sympathetic nervous system activation in human heart failure: clinical implications of an updated model. J Am Coll Cardiol 54(5):375-385, 2009.